Clinical Trials | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
The EBUS is designed to support the diagnosis and staging of various lung disorders
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
It is currently available in tablet and injectable dosage forms
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated
